Sanofi to acquire Dren Bio's immunology unit
Tweet
Share
E-mail
FILE PHOTO: A logo of Sanofi is seen at the Sanofi's Doliprane production site in Compiegne, France, October 17, 2024. REUTERS/Sarah Meyssonnier/File Photo
(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement.
The transaction is expected to close in the second quarter of 2025, it added.
(Reporting by Alban Kacher)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Discovery Energy Metals plans private placement of up to $1.25M
- One killed in drone attack on vessels in Taganrog Bay, Russian authorities say
- Beamr video compression listed on RTMaps AI Store for AV development
Create E-mail Alert Related Categories
ReutersRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
